Published in PLoS One on May 27, 2015
IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study. PLoS Med (2016) 0.83
Correction: Selective Targeting of CTNNB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs. PLoS One (2015) 0.75
Feedback activation of AMPK-mediated autophagy acceleration is a key resistance mechanism against SCD1 inhibitor-induced cell growth inhibition. PLoS One (2017) 0.75
Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administration-Approved Drugs. Pharmacol Rev (2017) 0.75
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
The druggable genome. Nat Rev Drug Discov (2002) 13.61
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res (2010) 12.96
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39
Cancer drug resistance: an evolving paradigm. Nat Rev Cancer (2013) 6.77
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 6.55
Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol (2011) 5.65
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov (2012) 4.72
A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci U S A (2004) 3.95
Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci U S A (2003) 3.86
The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res (2012) 3.36
Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res (2004) 3.13
Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol (2012) 3.10
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A (2009) 2.77
High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A (2014) 2.50
Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res (2004) 2.37
STK33 kinase activity is nonessential in KRAS-dependent cancer cells. Cancer Res (2011) 2.29
Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov (2011) 2.01
Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways. Thyroid (2008) 1.93
Systematic exploration of synergistic drug pairs. Mol Syst Biol (2011) 1.89
Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood (2010) 1.76
Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression. Nucleic Acids Res (2008) 1.66
Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proc Natl Acad Sci U S A (2010) 1.65
Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc Natl Acad Sci U S A (2012) 1.65
Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Sci Signal (2010) 1.64
Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int J Cancer (2002) 1.53
Applying synthetic lethality for the selective targeting of cancer. N Engl J Med (2014) 1.44
Myc and mammary cancer: Myc is a downstream effector of the ErbB2 receptor tyrosine kinase. J Mammary Gland Biol Neoplasia (2001) 1.39
Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. Cell Rep (2014) 1.37
Development of therapeutic combinations targeting major cancer signaling pathways. J Clin Oncol (2013) 1.30
c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer. Oncogene (2013) 1.29
Design and analysis of drug combination experiments. Biom J (2005) 1.23
CK1epsilon is required for breast cancers dependent on beta-catenin activity. PLoS One (2010) 1.22
A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer. Clin Cancer Res (2014) 1.11
Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck. Oncotarget (2011) 1.10
Oncogenic K-ras "addiction" and synthetic lethality. Cell Cycle (2009) 1.08
Molecular-targeted agents combination therapy for cancer: developments and potentials. Int J Cancer (2013) 1.05
The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. Br J Cancer (2012) 1.03
Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions. PLoS One (2013) 1.02
Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer. Br J Cancer (2013) 1.01
De novo synthesis of {beta}-catenin via H-Ras and MEK regulates airway smooth muscle growth. FASEB J (2009) 0.99
Cancer. Taking a back door to target Myc. Science (2012) 0.98
Vascular Endothelial Growth Factor Receptor-1 Is Synthetic Lethal to Aberrant {beta}-Catenin Activation in Colon Cancer. Clin Cancer Res (2009) 0.98
RNAi-mediated knockdown of AURKB and EGFR shows enhanced therapeutic efficacy in prostate tumor regression. Gene Ther (2009) 0.97
A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets. Br J Pharmacol (2012) 0.97
Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem (2010) 0.92
A theoretical entropy score as a single value to express inhibitor selectivity. BMC Bioinformatics (2011) 0.85
Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use. PLoS One (2014) 0.85
Non-incidental coamplification of Myc and ERBB2, and Myc and EGFR, in gastric adenocarcinomas. Mod Pathol (2007) 0.83
Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. Int J Urol (2006) 0.82
Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use. PLoS One (2014) 0.85
High-throughput fluorescence-based screening assays for tryptophan-catabolizing enzymes. J Biomol Screen (2014) 0.79
Structural modeling of JAK1 mutations in T-cell acute lymphoblastic leukemia reveals a second contact site between pseudokinase and kinase domains. Haematologica (2016) 0.76
Identification of an evolutionary conserved structural loop that is required for the enzymatic and biological function of tryptophan 2,3-dioxygenase. Sci Rep (2016) 0.75
Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines. Oncotarget (2017) 0.75